'Next Generation' cancer treatment ready for clinical trials

(Medical Xpress) -- A new class of anti-cancer drugs which control the growth and spread of cancers and do so with minimal side effects is being developed by researchers at the University of Sydney.

"These new agents attack a fundamental characteristic of while leaving normal cells alone," said Professor Des Richardson, from the Bosch Institute in Sydney Medical School.

"They work by binding the iron in , preventing them from growing. We believe they have the potential to be an effective new strategy, to be 'next generation' drugs, for a range of cancers including highly aggressive .

Because they do not act on non-cancerous cells these new agents dramatically reduce a range of distressing side effects familiar to people undergoing cancer treatments such as chemotherapy and radiotherapy.

Professor Richardson is the head of the and Chelation Program at the University and has been conducting research in this area since the early 1990s.

The latest research on the chelators is led by post-doctoral researcher and NHMRC Early Career Fellow, Dr. Zaklina Kovacevic.

In the Journal of Biological Chemistry, published today, the researchers outline how these new agents increase the levels of a molecule (NDRG1) which inhibits the spread of cancer, including prostate and colon cancers.

"Together with a recent article in the journal, Antioxidants and Redox Signaling, these studies advance our knowledge of cancer cell biology and how we can target specific molecules to stop cancer progressing," Dr. Kovacevic said.

Professor Richardson is currently in advanced discussions on a licensing deal with an American company for developing the compound to the stage of clinical trials.

"This will present a significant step forward in the fight against cancer and provide cancer sufferers new hope for a better outcome," Professor Richardson said.

"It is a difficult step to go from the often quoted bench to bedside, but it has been greatly helped by the Bosch Institute's Translational Grants program, and by an NHMRC Development Grant."

The Executive Director of the Bosch Institute, Professor Jonathan Stone stated: "For anyone who has been through, or cared for a cancer sufferer through, the purgatory of chemotherapy, the prospect of anti-cancer drugs which are broadly effective but with few side effects is immensely welcome."

add to favorites email to friend print save as pdf

Related Stories

Match your treatment to your cancer

Jun 30, 2011

(Medical Xpress) -- New research has uncovered why certain cancers don’t respond to conventional chemotherapy, highlighting the need to match treatments to cancers better.

Silencing a deadly conversation in breast cancer

Jun 02, 2011

While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning ...

Recommended for you

US women's awareness of breast density varies

8 hours ago

Disparities in the level of awareness and knowledge of breast density exist among U.S. women, according to the results of a Mayo Clinic study published in the Journal of Clinical Oncology.

Study shows why some brain cancers resist treatment

8 hours ago

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.

Researchers identify genes responsible for lung tumors

10 hours ago

The lung transcription factor Nkx2-1 is an important gene regulating lung formation and normal respiratory functions after birth. Alterations in the expression of this transcription factor can lead to diseases such as lung ...

Lycopene may ward off kidney cancer in older women

11 hours ago

A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.